Personalis

Personalis Net Margin

The Net Profit Margin of Personalis (PSNL) as of Oct 11, 2026 is -116.69 %. In the previous year, Net Profit Margin was -96.06 % — a change of 21.47% (lower).

Net Margin

-116.69 %

YoY

21.47%

Last updated:

Net Profit Margin of Personalis is 2025 -116.69 % . Net Profit Margin of Personalis was 2024 -96.06 % . It decreases by 21.47% lower compared to the previous year.

For Personalis, the net margin of -117.0% is down versus -76.5% a few years ago.

The Personalis Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-52.64 USD
Jan 1, 2019
-38.47 USD
Jan 1, 2020
-52.49 USD
Jan 1, 2021
-76.29 USD
Jan 1, 2022
-174.20 USD
Jan 1, 2023
-147.38 USD
Jan 1, 2024
-96.06 USD
Jan 1, 2025
-116.69 USD
The Personalis Net Margin history
YEARNet MarginYoY
-116.69 %+21.47%
-96.06 %-34.82%
-147.38 %-15.40%
-174.20 %+128.34%
-76.29 %+45.36%
-52.49 %+36.44%
-38.47 %-26.93%
-52.64 %-79.05%
-251.23 %—
Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

Net Profit Margin of Personalis is -116.69 % in 2025.

Net Profit Margin of Personalis changed from -96.06 % to -116.69 %, representing a 21.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Personalis since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Personalis with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Personalis

All Key Metrics — Personalis